NJNicholas E. Johnson

Nicholas E. Johnson

*This is an algorithmically generated author record based on publicly available information.

Nicholas E. Johnson has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Man Hung

    Department of Orthopedics University of Utah Salt Lake City UT

    4 shared publications
  • Nuran Dilek

    Department of Neurology University of Rochester Rochester NY

    4 shared publications
  • Chad R. Heatwole

    The Department of Neurology, University of Rochester, NY, USA

    3 shared publications
  • David N. Herrmann

    Department of Neurology University of Rochester Rochester NY

    3 shared publications
  • Michael E. Shy

    Department of Neurology, Carver College of Medicine University of Iowa Iowa City Iowa USA

    3 shared publications
  • Wei Chen

    From the Departments of Neurology (N.E.J., R.B., K.B., D.D., M.D., E.P.), Orthopaedics (M.H., J.B.), and Physical Therapy (H.H.), and Division of Epidemiology (M.H., W.C.), The University of Utah, Salt Lake City; Department of Neurology (C.H.), The University of Rochester, NY; and Departments of Pediatrics, Clinical Neurological Sciences, and Epidemiology (C.C.), Western University, London, Canada

    3 shared publications

Latest Publications

  • The Charcot–Marie–Tooth Health Index: Evaluation of a Patient‐Reported Outcome

    by Nicholas E. Johnson, Chad Heatwole, Peter Creigh, Michael P. McDermott, Nuran Dilek, Man Hung, Jerry Bounsanga Bs, Wan Tang, Michael E. Shy, David N. Herrmann

    Objective: The development of a disease‐specific patient‐reported outcome for Charcot–Marie–Tooth disease is an important step in the preparation for therapeutic trials. This study describes the development of the Charcot–Marie–Tooth Health Index (CMTHI).Methods: Inherited Neuropathy Consortium Contact Registry participants were queried on the symptoms that most impacted their lives. The CMTHI was developed based on these responses. Factor analysis, assessment of test–retest reliability, known group validity, and patient interviews were utilized to refine the instrument.Results: The final CMTHI contains 18 themes that capture Charcot–Marie–Tooth disease (CMT) burden. The CMTHI has a high internal consistency and test–retest reliability. The CMTHI was able to discriminate between patient groups expected to have different disease burden. The CMTHI was able to discriminate levels of disability as measured by the CMT examination score and the mobility‐Disability Severity Index.Interpretation: The CMTHI represents a valid and reliable outcome to assess patient‐reported disease burden in CMT. Ann Neurol 2018;84:225–233


  • Patient-Centered Therapy Development for Myotonic Dystrophy: Report of the Myotonic Dystrophy Foundation–Sponsored Workshop

    by Sharon Hesterlee, Shashi Amur, Lisa J. Bain, John Carulli, Sarah Clarke, John W. Day, Cynthia Gagnon, Katharine Hagerman, Chad Heatwole, Nicholas E. Johnson, et al.


  • Disease burden and functional outcomes in congenital myotonic dystrophy

    by Nicholas E. Johnson, Russell Butterfield, Kiera Berggren, Man Hung, Wei Chen, Deanna DiBella, Melissa Dixon, Heather Hayes, Evan Pucillo, Jerry Bounsanga, et al.

    Objective: Herein, we describe the disease burden and age-related changes of congenital-onset myotonic dystrophy (CDM) in childhood. Methods: Children with CDM and age-matched controls aged 0 to 13 years were enrolled. Participants were divided into cohorts based on the following age groups: 0–2, 3–6, and 7–13 years. Each cohort received age-appropriate evaluations including functional testing, oral facial strength testing, neuropsychological testing, quality-of-life measurements, and ECG. Independent-samples t test or Wilcoxon 2-sample test was used to compare the differences between children with CDM and controls. Probability values less than 0.05 are reported as significant. Results: Forty-one participants with CDM and 29 healthy controls were enrolled. The 6-minute walk was significantly different between CDM (258.3 m [SD 176.0]) and control participants (568.2 m [SD 73.2]). The mean lip force strength was significantly different in CDM (2.1 N [SD 2.8)] compared to control participants (17.8 N [SD 7.6]). In participants with CDM, the mean IQ (65.8; SD 18.4) was 3 SDs below the mean compared to standardized norms. Measurements of grip strength, sleep quality, and quality of life were also significantly different. Strength measures (oral facial strength, grip strength, and 6-minute walk) correlated with each other but not with participant IQ. Conclusions: This work identifies important phenotypes associated with CDM during childhood. Several measures of strength and function were significantly different between participants with CDM and controls and may be useful during future therapeutic trials.


  • Neurology Advocacy 2.0

    by Nicholas E. Johnson, Amy Kaloides, Elaine Jones

    This Viewpoint examines the reforms needed in the field of neurology after the repeal of the sustainable growth rate.


  • Open Access

    Management of Charcot–Marie–Tooth disease: improving long-term care with a multidisciplinary approach

    by Nicholas Johnson, Donald McCorquodale, Evan Pucillo

    Charcot–Marie–Tooth (CMT) disease is the most common inherited neuropathy and one of the most common inherited diseases in humans. The diagnosis of CMT is traditionally made by the neurologic specialist, yet the optimal management of CMT patients includes genetic counselors, physical and occupational therapists, physiatrists, orthotists, mental health providers, and community resources. Rapidly developing genetic discoveries and novel gene discovery techniques continue to add a growing number of genetic subtypes of CMT. The first large clinical natural history and therapeutic trials have added to our knowledge of each CMT subtype and revealed how CMT impacts patient quality of life. In this review, we discuss several important trends in CMT research factors that will require a collaborative multidisciplinary approach. These include the development of large multicenter patient registries, standardized clinical instruments to assess disease progression and disability, and increasing recognition and use of patient-reported outcome measures. These developments will continue to guide strategies in long-term multidisciplinary efforts to maintain quality of life and preserve functionality in CMT patients.


  • Open Access

    Whole-exome sequencing in neurologic practice

    by Nicholas E. Johnson

    The current issue of Neurology® Genetics emphasizes the unparalleled role of next-generation sequencing (NGS) in defining an expanding spectrum of genetic neurologic disorders. Clinically, NGS encompasses the use of large gene panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS). The impact of NGS technology is twofold. First, researchers have discovered novel genes as the cause of neurologic disorders. This research includes the efforts of Martikainen et al.(1) to define further the phenotype of a previously reported SNCA mutation that is associated with autosomal dominant Parkinson disease. Second and more common is the connection of novel phenotypes with previously described genes. Several articles in the current issue highlight the role of NGS in this effort. For example, Schottman et al.(2) identified REEP1 mutations as the cause of a severe axonal neuropathy with a spinal muscular atrophy with respiratory distress (SMARD) phenotype. This gene was previously associated with a hereditary spastic paraplegia phenotype. Similarly, Shieh et al.(3) expand the phenotype associated with mutations in L1CAM to a neuronal migration phenotype.


  • Open Access

    Parent‐reported multi‐national study of the impact of congenital and childhood onset myotonic dystrophy

    by Nicholas E Johnson, Anne‐Berit Ekstrom, Craig Campbell, Man Hung, Heather R Adams, Wei Chen, Elizabeth Luebbe, James Hilbert, Richard T Moxley, Chad R Heatwole

    Aim: The frequency and impact of symptoms experienced by patients with congenital, childhood, and juvenile‐onset myotonic dystrophy (CDM/ChDM/JDM) is not documented. This report identifies symptomatic areas with the greatest disease burden in an international population of patients with early‐onset myotonic dystrophy type‐1 (DM1).Method: We distributed surveys to parents of patients with CDM/ChDM/JDM. Patients with CDM/ChDM/JDM were members of the US National Registry of DM1 Patients and Family Members, the Canadian Neuromuscular Disease Registry, or the Swedish Health System. Surveys inquired about 325 symptoms and 20 themes associated with CDM/ChDM/JDM. Parents identified the importance of each symptom and theme to their affected child. The prevalence of each symptom and theme were compared across subgroups of patients. The statistical analysis was performed using Fisher's exact and Kruskal–Wallis tests.Results: One hundred and fifty parents returned surveys. The most frequently reported symptomatic themes in children were issues involving communication (81.7%) and problems with hands or fingers (79.6%). Problems with communication and fatigue were the issues that were reported to have the greatest impact on childrens’ lives, while 24.1% of children reported cardiac disorders and 15.8% had problems with anesthesia.Interpretation: A range of symptoms contribute to the burden of disease faced by children with DM1. Many of these symptoms are under‐recognized.


  • Open Access

    The Impact of Pregnancy on Myotonic Dystrophy: A Registry-Based Study

    by Nicholas E. Johnson, Man Hung, Eriko Nasser, Katharine A. Hagerman, Wei Chen, Emma Ciafaloni, Chad R. Heatwole

    Background: The rate of symptom progression during pregnancy in myotonic dystrophy (DM) is not currently known. Further, there is little data regarding the rate of pregnancy complications and neonatal outcomes in DM. Objective: This study assesses symptom progression and complication rates during pregnancy in women with DM. Methods: DM women completed surveys regarding their prior pregnancies. Participants identified complications during their pregnancies and completed the Myotonic Dystrophy Health Index-Short Form (MDHI-SF) to measure their disease burden and identify the severity of select symptoms six-months prior to, during, and six-months after their first pregnancy. Results: 152 women with DM reported on 375 pregnancies. Among these pregnancies, there was a 32.5% miscarriage rate. Some complications were common including: pre-term labor (27.8%), pre-eclampsia (10.4%), and peripartum hemorrhage (13.9%). Participants’ perception of their mobility and ability to perform activities, as measured by the MDHI-SF, worsened during pregnancy and did not recover during the post-partum period. Discussion: Miscarriage, maternal disease progression during pregnancy, and other pregnancy related complications may occur in DM. Women with DM should be counseled on these potential risks prior to considering pregnancy.


  • Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients

    by Nicholas E. Johnson, W. David Arnold, Donald Hebert, Kelly Gwathmey, Mazen M. Dimachkie, Richard J. Barohn, April L. McVey, Mamatha Pasnoor, Anthony A. Amato, Michael P. McDermott, et al.


  • Relative risks for comorbidities associated with myotonic dystrophy: A population‐based analysis

    by Nicholas E. Johnson, Diana Abbott, Lisa A. Cannon‐Albright

    Introduction: A population‐level relative risk assessment for comorbidities associated with myotonic dystrophy has not been performed. Methods: In this study we utilized the Utah Population Database to identify patients with myotonic dystrophy in Utah according to ICD‐9 coding. Comorbidity cases listed in the medical record were compared with those of the Utah population. Results: Individuals with myotonic dystrophy were found to possess an increased risk of central and obstructive sleep apnea, hypothyroidism, and intellectual disability. The risk of cardiac conduction disorder is 60 times the population risk. Conclusions: This study provides a population‐level relative risk assessment of comorbidities in myotonic dystrophy. This allows for improved counseling of patients regarding these increased risks. Muscle Nerve 52: 659–661, 2015